Rhythm Pharmaceuticals

OverviewSuggest Edit

Rhythm Pharmaceuticals is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.
TypePublic
Founded2008
HQBoston, MA, US
Websiterhythmtx.com

Latest Updates

Employees (est.) (Nov 2017)22(+23%)
Share Price (Sept 2021)$13(+2%)
Cybersecurity ratingBMore

Key People/Management at Rhythm Pharmaceuticals

Nithya Desikan

Nithya Desikan

Chief Commercial Officer
Hunter Smith

Hunter Smith

Chief Financial Officer
Simon Kelner

Simon Kelner

Chief Human Resources Officer
Murray Stewart

Murray Stewart

Chief Medical Officer
David Meeker

David Meeker

Chairman, President and Chief Executive Officer
Show more

Rhythm Pharmaceuticals Office Locations

Rhythm Pharmaceuticals has an office in Boston
Boston, MA, US (HQ)
222 Berkeley St # 12
Show all (1)

Rhythm Pharmaceuticals Financials and Metrics

Rhythm Pharmaceuticals Revenue

USD

Net income (Q3, 2017)

(10.0m)

EBIT (Q3, 2017)

(8.3m)

Market capitalization (9-Sept-2021)

652.7m

Closing stock price (9-Sept-2021)

13.0

Cash (30-Sept-2017)

27.9m
Rhythm Pharmaceuticals's current market capitalization is $652.7 m.
Annual
USDFY, 2015FY, 2016

General and administrative expense

3.4m6.3m

R&D expense

7.1m19.6m

Operating expense total

10.6m25.9m

EBIT

(10.6m)(25.9m)
Quarterly
USDQ3, 2016Q3, 2017

General and administrative expense

982.0k2.3m

R&D expense

5.4m6.0m

Operating expense total

6.4m8.3m

EBIT

(6.4m)(8.3m)
Annual
USDFY, 2015FY, 2016

Cash

34.9m6.5m

Prepaid Expenses

623.0k638.0k

Current Assets

35.5m11.2m

PP&E

17.0k930.0k
Quarterly
USDQ2, 2017Q3, 2017

Cash

8.7m27.9m

Prepaid Expenses

722.0k1.6m

Current Assets

18.5m32.0m

PP&E

822.0k845.0k
Annual
USDFY, 2015FY, 2016

Net Income

(11.1m)(25.9m)

Depreciation and Amortization

144.0k

Accounts Payable

893.0k467.0k

Cash From Operating Activities

(7.0m)(23.2m)
Quarterly
USDQ2, 2016Q3, 2016Q2, 2017Q3, 2017

Net Income

(11.1m)(17.5m)(13.2m)(23.2m)

Depreciation and Amortization

33.0k89.0k108.0k163.0k

Accounts Payable

882.0k(335.0k)(602.0k)830.0k

Cash From Operating Activities

(12.6m)(17.0m)(13.2m)(21.6m)
USDFY, 2015

Financial Leverage

-4.7 x
Show all financial metrics

Rhythm Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Rhythm Pharmaceuticals Online and Social Media Presence

Embed Graph

Rhythm Pharmaceuticals News and Updates

Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive…

Rhythm Pharmaceuticals to Present at the 59th Annual ESPE Meeting

Company announces acceptance of seven abstracts with data from multiple clinical trials evaluating setmelanotide for rare genetic diseases of obesity Company announces acceptance of seven abstracts with data from multiple clinical trials evaluating setmelanotide for rare genetic diseases of obesity

Rhythm Pharmaceuticals to Present at 2021 Canaccord Genuity 41st Annual Growth Conference

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive …

Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results

-- Received European Commission authorization of IMCIVREE for treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficiencies ---- Setmelanotide selected for evaluation as a “Highly Specialised Technology” by Great Britain’s National Institute for Health and Care Excelle…

Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity

-- Pivotal Phase 3 EMANATE trial planned in patients with heterozygous POMC, PCSK1 or LEPR, and SRC1 or SH2B1 deficiency obesities ---- EMANATE, as well as Phase 2 DAYBREAK trial evaluating setmelanotide in 31 new genes, Phase 3 pediatrics trial and Phase 3 trials of weekly setmelanotide formulation…

Rhythm Pharmaceuticals Announces Senior Leadership Additions

-- Pamela Cramer appointed Chief Human Resources Officer -- -- Linda Shapiro Manning, M.D., Ph.D., appointed Senior Vice President, Clinical --
Show more

Rhythm Pharmaceuticals Blogs

Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome Content Import Wed, 09/08/2021 - 16:02 Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome Septem…

Rhythm Pharmaceuticals Announces CMO Transition

Rhythm Pharmaceuticals Announces CMO Transition Content Import Thu, 09/02/2021 - 16:01 Rhythm Pharmaceuticals Announces CMO Transition September 2, 2021 at 4:01 PM EDT This release is a backfill from a News Wire General -- Linda Shapi…

Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome Content Import Wed, 07/28/2021 - 16:02 Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome …

Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021

-- Responders with HET obesity achieved mean weight loss of greater than 12 percent at nine months on setmelanotide therapy -- -- Additional poster presentations include Phase 3 data in Bardet-Biedl and Alström syndromes and analyses of adverse events   in Phase 2 and Phase 3 studies in POMC,

Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M

BOSTON , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has entered into a definitive agreement to sell its

Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020

Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020 Content Import Wed, 11/04/2020 - 16:31 Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020 November 4, 2020 at 4:30 PM EST This releas…
Show more

Rhythm Pharmaceuticals Frequently Asked Questions

  • When was Rhythm Pharmaceuticals founded?

    Rhythm Pharmaceuticals was founded in 2008.

  • Who are Rhythm Pharmaceuticals key executives?

    Rhythm Pharmaceuticals's key executives are Nithya Desikan, Hunter Smith and Simon Kelner.

  • How many employees does Rhythm Pharmaceuticals have?

    Rhythm Pharmaceuticals has 22 employees.

  • Who are Rhythm Pharmaceuticals competitors?

    Competitors of Rhythm Pharmaceuticals include EMS Pharma, PPD and Genentech.

  • Where is Rhythm Pharmaceuticals headquarters?

    Rhythm Pharmaceuticals headquarters is located at 222 Berkeley St # 12, Boston.

  • Where are Rhythm Pharmaceuticals offices?

    Rhythm Pharmaceuticals has an office in Boston.

  • How many offices does Rhythm Pharmaceuticals have?

    Rhythm Pharmaceuticals has 1 office.